Investors are excited about technologies like mRNA and genomics, along with a steady stream of new drug approvals. The FDA approved about a dozen novel biologic drugs in 2025, out of 46 approvals in total. Roughly 66 novel drugs are in the pipeline for FDA approval, including potential blockbusters like Moderna and Merck's cancer drug for melanoma, and a next-generation obesity drug from Eli Lilly. Stock Chart IconStock chart icon iShares Biotechnology ETF (IBB), YTD Analysts say AI could also lead to more ...